Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

Apr 01, 2022

Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights

Mar 28, 2022

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Mar 28, 2022

Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Mar 23, 2022

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Mar 23, 2022

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting

Mar 21, 2022

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

Mar 18, 2022

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

Mar 17, 2022

Mustang Bio to Participate in Three March 2022 Investor Conferences

Mar 10, 2022

Fortress Biotech to Participate in Three March 2022 Investor Conferences

Mar 09, 2022
RSS
  • Prev
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...52
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2023 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap